NEW YORK (GenomeWeb News) — Amaxa said today that it will coordinate an eight-member European alliance to develop devices for ultra-high-throughput transfection of primary cells.
The European Commission awarded the partnership more than €2.75 million ($3.7 million) in funding. The group will use Amaxa’s Nucleofector technology, the company said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.